Air Pollution and Health of COPD Patients


This panel study aims to evaluate the effects of air pollutants on cardiopulmonary health of patients with chronic obstructive pulmonary disease (COPD) and explore the potential biological mechanisms.

Full Title of Study: “Effect of Air Pollution on Prognosis of Patients With Chronic Obstructive Pulmonary Disease and Its Underlying Biological Mechanism”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 31, 2022

Detailed Description

This panel study was conducted in a group of stable patients with COPD in Beijing, China. The health measurements including lung function, blood pressure and airway inflammation were conducted, and morning urine, exhaled breath condensate, saliva and venous blood were collected at the time of enrollment and at 3, 6 and 9 months after enrollment. Individual exposures to fine particulate matter (PM2.5), black carbon (BC), ozone (O3) and nitrogen dioxide (NO2) were performed for 24 hours at each follow-up. And the daily concentrations of air pollutants were collected from the Beijing Air Quality Real-time Publishing Platform and meteorological data were collected from the National Meteorological Information Center. The linear mixed effects model was used to analyze the association between air pollution and cardiopulmonary health in patients with COPD.


  • Other: Air pollutants
    • Particulate matter and gaseous pollutants

Clinical Trial Outcome Measures

Primary Measures

  • Lung function
    • Time Frame: Nine months
    • Lung function test was conducted.

Secondary Measures

  • COPD Assessment Test scores
    • Time Frame: Nine months
    • COPD Assessment Test (CAT) scores were used to assess quality of life in COPD patients on a scale of 0 to 40, with higher scores associated with poorer outcomes.
  • Modified British Medical Research Council (mMRC) Questionnaire score
    • Time Frame: Nine months
    • Modified British Medical Research Council (mMRC) Questionnaire score was used to assess the severity of dyspnea on a scale of 0 to 4, with a higher score indicating a worse outcome.
  • ST. George’s Respiratory Questionnaire scores
    • Time Frame: Nine months
    • ST. George’s Respiratory Questionnaire (SGRQ) scores were used to assess quality of life in patients with COPD on a scale of 0 to 100, with higher scores indicating poorer outcomes.
  • Blood pressure
    • Time Frame: Nine months
    • Systolic and diastolic blood pressure of participants were measured at least three times by a trained technician.
  • Respiratory inflammation
    • Time Frame: Nine months
    • Fractional exhaled nitric oxide (FeNO) test was conducted.
  • Airway and systemic oxidative stress levels
    • Time Frame: Nine months
    • Exhaled Breath Condensate (EBC) and urine samples were collected for oxidative stress analysis.
  • Systemic inflammation
    • Time Frame: Nine months
    • Venous blood was collected for determination of systemic inflammatory biomarkers.

Participating in This Clinical Trial

Inclusion Criteria

  • doctor-diagnosed stable COPD patients – aged 40 to 80 years – lived in Beijing for over one year before being recruited – Agree to participate and sign the informed consent form. Exclusion Criteria:

  • Patients with a history of acute exacerbation in the last 1 month – Patients with other respiratory diseases such as bronchiectasis and asthma.

Gender Eligibility: All

Minimum Age: 40 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Peking University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Furong Deng, Deputy Director of Department of Occupational and Environmental Health Sciences – Peking University
  • Overall Official(s)
    • Furong Deng, Doctor, Principal Investigator, Peking University
  • Overall Contact(s)
    • Furong Deng, Doctor, 010-82805779,

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.